Takeda Pharmaceutical Co. Ltd.’s U.S. FDA go-ahead for Mimrylo (rusfertide) to treat erythrocytosis in adults with polycythemia vera (PV) came as little surprise, given the stellar phase III data that the hepcidin mimetic has yielded.
Takeda Pharmaceutical Co. Ltd.’s U.S. FDA go-ahead for Mimrylo (rusfertide) to treat erythrocytosis in adults with polycythemia vera (PV) came as little surprise, given the stellar phase III data that the hepcidin mimetic has yielded.